D. Peckham

8.3k total citations
203 papers, 3.5k citations indexed

About

D. Peckham is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, D. Peckham has authored 203 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Pulmonary and Respiratory Medicine, 26 papers in Physiology and 24 papers in Epidemiology. Recurrent topics in D. Peckham's work include Cystic Fibrosis Research Advances (118 papers), Neonatal Respiratory Health Research (23 papers) and Tracheal and airway disorders (22 papers). D. Peckham is often cited by papers focused on Cystic Fibrosis Research Advances (118 papers), Neonatal Respiratory Health Research (23 papers) and Tracheal and airway disorders (22 papers). D. Peckham collaborates with scholars based in United Kingdom, United States and Ireland. D. Peckham's co-authors include Paul Whitaker, C. Etherington, I. Clifton, Michael McDermott, S.P. Conway, M. Denton, Jonathan Holbrook, Heledd Jarosz-Griffiths, Alan J. Knox and Samuel Lara‐Reyna and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and PLoS ONE.

In The Last Decade

D. Peckham

186 papers receiving 3.4k citations

Peers

Countries citing papers authored by D. Peckham

Since Specialization

Citations

This map shows the geographic impact of D. Peckham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Peckham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Peckham more than expected).

Fields of papers citing papers by D. Peckham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Peckham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Peckham. The network helps show where D. Peckham may publish in the future.

Co-authorship network of co-authors of D. Peckham

This figure shows the co-authorship network connecting the top 25 collaborators of D. Peckham. A scholar is included among the top collaborators of D. Peckham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Peckham. D. Peckham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis 2025 ·Journal of Cystic Fibrosis ·(unknown), (unknown), (unknown), (unknown), (unknown), Helen White, (unknown), D. Peckham	3
2	Phenotypic and functional characterisation of liver-infiltrating T-cells in a case of CFTR modulator induced drug-induced liver injury 2025 ·Journal of Cystic Fibrosis ·(unknown), Joshua Gardner, (unknown), (unknown), Jobst Roehmel, Paul Whitaker, Phaedra Tachtatzis, (unknown), D. Peckham, Dean J. Naisbitt	0
3	Managing an ageing cystic fibrosis population: challenges and priorities 2025 ·European Respiratory Review ·Freddy Frost, D. Peckham, (unknown), (unknown), Robert D. Gray, Andrew Jones, Nicholas J. Simmonds, Robert Lord, Gregory Y.H. Lip, (unknown), Kevin P. Murphy, D.G. Downey, David N. Sheppard, Jane C. Davies, John Bull, Paula Sommer, (unknown), Lucy Allen, J. Duckers	0
4	P15-14 Characterisation of liver-derived T-cells during and upon resolution of CFTR modulator induced liver injury 2024 ·Toxicology Letters ·Emily J. Clarke, Julie M. Gardner, (unknown), D. Peckham, Xiaoli Meng, Dean J. Naisbitt	0
5	FACS-based detection of extracellular ASC specks from NLRP3 inflammasomes in inflammatory diseases 2024 ·Clinical & Experimental Immunology ·Joanne Topping, Samuel Lara‐Reyna, (unknown), Heledd Jarosz-Griffiths, (unknown), James A. Poulter, D. Peckham, Michael McDermott, Sinisa Savic	1
6	WS07.06 Maternal and foetal outcomes following elexacaftor/tezacaftor/ivacaftor (ETI) use during pregnancy: comparison with pregnancy outcome data from the pre modulator era 2024 ·Journal of Cystic Fibrosis ·C. Etherington, (unknown), I. Clifton, Giulia Spoletini, D. Peckham	1
7	P303 Prevalence and clinical presentation of inflammatory bowel disease (IBD) in a large adult cystic fibrosis (CF) Unit 2024 ·Journal of Cystic Fibrosis ·(unknown), Louise Stone, (unknown), C. Etherington, I. Clifton, D. Peckham	1
8	Prevalence and Distribution of Musculoskeletal Symptoms in Cystic Fibrosis and Impacts on Daily Life 2024 ·Pediatric Pulmonology ·(unknown), (unknown), Pippa Watson, Jane Freeston, Andrew Jones, D. Peckham, Alex Horsley	0
9	Role of inhaled antibiotics in the era of highly effective CFTR modulators 2023 ·European Respiratory Review ·J.S. Elborn, Francesco Blasi, Pierre‐Régis Burgel, D. Peckham	32
10	Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis 2023 ·Journal of Cystic Fibrosis ·(unknown), Heledd Jarosz-Griffiths, Lesley Smith, (unknown), Joanne Barrett, (unknown), (unknown), M. Nash, Andrew Jones, J.L. Whitehouse, (unknown), R. Andres Floto, H. White, D. Peckham	19
11	The gut microbiota in adults with cystic fibrosis compared to colorectal cancer 2023 ·Journal of Cystic Fibrosis ·(unknown), Henry M. Wood, (unknown), (unknown), (unknown), J. E. Dyson, Caroline Young, H. White, Sally C. Benton, M. J. Brearley, Philip Quirke, D. Peckham	1
12	A mathematical model for assessing transient airborne infection risks in a multi-zone hospital ward 2023 ·Building and Environment ·(unknown), Lee Benson, (unknown), Martín López‐García, Catherine J. Noakes, D. Peckham, Marco‐Felipe King	10
13	Ways of coping and survival in Cystic Fibrosis: a 20-year longitudinal study 2022 ·Journal of Cystic Fibrosis ·Janice Abbott, M. A. Hurley, (unknown), D. Peckham	6
14	Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era 2022 ·Current Opinion in Pulmonary Medicine ·Michael Wilschanski, D. Peckham	6
15	Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study 2021 ·Journal of Cystic Fibrosis ·Olga Archangelidi, Paul Cullinan, Nicholas J. Simmonds, Emmanouil Mentzakis, D. Peckham, Diana Bilton, S.B. Carr	18
16	ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis 2019 ·eLife ·Thomas Scambler, Heledd Jarosz-Griffiths, Samuel Lara‐Reyna, Shelly Pathak, Chi Huey Wong, Jonathan Holbrook, Fabio Martinon, Sinisa Savic, D. Peckham, Michael McDermott	86
17	Requirements and access needs of patients with chronic disease to their hospital electronic health record: results of a cross-sectional questionnaire survey 2016 ·BMJ Open ·H. White, (unknown), (unknown), D. Peckham	8
18	Safety and efficacy of 7% hypertonic saline in patients with bronchiectasis 2013 ·European Respiratory Journal ·(unknown), (unknown), Toby Capstick, D. Peckham, I. Clifton	0
19	294 Survey of contraceptive practices in women attending a large regional UK centre 2012 ·Journal of Cystic Fibrosis ·C. Etherington, Scott F. Huntington, S.P. Conway, D. Peckham	3
20	Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis 2011 ·Journal of Allergy and Clinical Immunology ·(unknown), José Luis Castrejón-Flores, Sidonie N. Lavergne, Paul Whitaker, Manal Monshi, (unknown), Sabah H. El-Ghaiesh, John Farrell, Werner J. Pichler, D. Peckham, B. Kevin Park, Dean J. Naisbitt	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact